3Nowotnik DP, Canning LR, Cumming SA, et al. Development of a ^99mTc-labelled radiopharmaceutical for cerebral blood flow imaging[J].Nucl Med Commun, 1985,6(9) :499-506.
4Holmes RA, Chaplin SB, Royston KG, et al. Cerebral uptake and retention of ^99mTc-hexamethylpropyleneamine oxime(99mTc-HMPAO) [J].Nucl Med Commun, 1985,6(8):443-447.
5Leveille J, Demonceau G, Rigo P, et al. Brain tomographic imaging with ^99mTc-ethyl cysteinate dimer(^99mTc-ECD) :a new stable brain perfusion agent[J] .J Nucl Med, 1988,29(5) :758.
6Demonceau G, Leveille J, De Boo M, et al. Comparison of ^99mTc ECD and 99mTc-HMPAO:first human results[J] .J Nucl Med, 1988,29(5) :747.
7Winchell HS, Baldwin RM, Lin TH: Development of 1-123-l abeledamines for brain studies: Localization of I-123 iodophenylalkyl amines in rat brain[J]. J Nucl Med, 1980,21(10) :940-947.
8Camargo EE. Brain SPECT in neurology and psychiatry [ J ]. J Nucl Med,2001,42(4) :611-623.
9Bogousslavsky J, Delaloye-Bischof A, Regli F, et al. Prolonged hypoperfusion and early stroke after transient ischemic attack[J]. Stroke,1990,21(1) :40-46.
10Matti-Fabregas JA, Catafau AM, Mendpza G, et al. Cerebral perfusion and haemodynamics measured by SPET in symptom-free patients with transient ischaemic attack: clinical implications[J]. Eur J Nucl Med,2001,28(12) : 1828-1835.
